Actively Recruiting
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-12-03
56
Participants Needed
7
Research Sites
261 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer. The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.
CONDITIONS
Official Title
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or over
- Diagnosed with advanced or metastatic cancer that has relapsed or is refractory to standard treatment in two prior therapies, or no standard treatment available
- At least two tumors suitable for direct or ultrasound-guided injection, with one lesion measurable by RECIST criteria
- Willing to undergo mandatory initial screening biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- No curative treatment options available or treatments cause significant morbidity
- Disease progressed on standard therapy or no standard therapy or contraindications to standard therapy
- Specific cancer types eligible as listed in study parts 1a, 2a, 1b, and 2b
- Predicted life expectancy of 3 months or more
- Able to provide written informed consent
- Ability to comply with study procedures
- Adequate renal function (creatinine <2 mg/dL)
- Adequate hepatic function with specified limits for bilirubin, AST, and ALT
- Adequate bone marrow and hematologic function including coagulation, platelets, and ANC
- Females of child-bearing potential must have negative pregnancy tests and agree to use contraception
- For part 2, at least one measurable disease site
- Prior non-immunotherapy cancer treatments discontinued >4 weeks before enrollment
- Patients who failed prior anti-PD1/-PDL1 therapies may be included with specified washout periods
- Patients with BRAF-mutated melanoma should have received BRAF-targeted therapy
You will not qualify if you...
- History of splenectomy
- Active infections requiring antibiotics or recurrent fevers >38.0 °C
- Active viral infections including hepatitis B, hepatitis C, or HIV with low CD4 count (<100/mm3)
- Incomplete recovery from surgery or incision site not healed
- Serious gastrointestinal bleeding or inflammatory bowel diseases within 3 months prior to treatment
- Recent significant cardiac events within 6 months before treatment
- Uncontrolled infections within 6 months prior to study entry
- Significant bleeding requiring hospitalization within 12 months prior to treatment
- Recent treatment with immune checkpoint inhibitors or immune-stimulatory therapies within 3 weeks prior to study
- Recent chemotherapy, radiotherapy, biological therapy, targeted therapy, investigational drugs, or major surgery within 28 days before enrollment
- Active central nervous system metastases or carcinomatous meningitis
- Received live vaccine within 28 days before enrollment
- Pregnant or breastfeeding, or planning to conceive or father children during the trial
- Tumors contacting or invading major blood vessels or hollow organs risking perforation
- Risk of airway compromise from tumor swelling
- History of autoimmune disease requiring systemic treatment in past 2 years
- History of chronic liver disease or cirrhosis
- History of lung diseases requiring systemic steroids
- Low baseline oxygen saturation (<92%) on room air
- History of re-irradiation involving carotid arteries
- History of certain leukemias unless in remission without immunosuppression
- Current use of high-dose steroids or immunosuppressants within 2 weeks prior to treatment
- Any serious medical or psychological conditions that increase risk or impair ability to participate
- Known allergy to MQ710 components
- Requirement for anticoagulation therapy such as warfarin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
Commack, New York, United States, 11725
Active, Not Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Active, Not Recruiting
6
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, United States, 10065
Actively Recruiting
7
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, United States, 11553
Actively Recruiting
Research Team
L
Lara Dunn, MD
CONTACT
A
Anthony Rossi, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here